Randy Schatzman
About Randy Schatzman
Randall Schatzman Chief Executive Officer at Bolt Biotherapeutics
Randall Schatzman assumed the role of Chief Executive Officer at Bolt Biotherapeutics in 2019. With over 30 years of experience in biotechnology, Schatzman brings an extensive background in leadership and innovation to the company.
Randall Schatzman's Role at Alder BioPharmaceuticals
Randall Schatzman co-founded Alder BioPharmaceuticals in 2004, where he served as president, CEO, and board member until 2018. During his tenure, he led the company through significant milestones, including the discovery and patenting of Vyepti (eptinezumab) for migraine prevention and clazakizumab for treating antibody-mediated kidney allograft failure.
Randall Schatzman's Leadership at Celltech R&D
At Celltech R&D, Randall Schatzman held the position of Senior Vice President of Discovery Research. He led the team responsible for discovering Evenity (romosozumab), a therapeutic subsequently licensed to Amgen in a 50/50 partnership.
Randall Schatzman's Early Career at Syntex/Roche Bioscience
Randall Schatzman worked at Syntex/Roche Bioscience, where he served as the preclinical team leader for Cytovene (ganciclovir) and team leader for Valcyte (valganciclovir hydrochloride). His roles involved leading crucial projects in the development of these therapeutics.
Randall Schatzman's Education and Research
Randall Schatzman earned his Ph.D. in molecular pharmacology from Emory University. He completed an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Schatzman holds over 30 issued patents and has authored more than 40 peer-reviewed scientific publications.